ARCADIA, Calif., May 4 /PRNewswire/ -- StemCyte, Inc., a privately held stem cell therapy and cord blood bank, with highly accredited processing and storage facilities in both the U.S. and Taiwan, recently shipped its 300th cord blood stem cell unit for transplant. This marks another milestone in the company’s rapid growth as one of the world’s leading providers of quality cord blood stem cell units. StemCyte has now provided cord blood units to over 95 transplant centers worldwide across 5 continents, with the number of units released for transplantation increasing rapidly. StemCyte’s units have been used for the treatment of over 40 diseases, including leukemias, lymphomas, immune diseases and genetic disorders.
“This is an especially exciting time for the cord blood stem cell industry as now more and more transplant centers are using cord blood for both children and adult transplantations,” says StemCyte’s CEO Ken Giacin. “We are also seeing more transplants for non-malignant diseases such as thalassemia, with several patients receiving double cord blood transplants, an exciting and cutting-edge protocol. StemCyte expects to grow rapidly in terms of the number of transplant centers that we serve and the number of patients whose lives are saved by our units.”
“We are very pleased with the growing vote of confidence that is being extended to StemCyte by transplant physicians around the world,” said Lawrence D. Petz, M.D., Chief Medical Officer, StemCyte International Cord Blood Center, and Emeritus Professor of Pathology and Laboratory Medicine, UCLA Medical Center. “Our consistently excellent one-year patient survival data continue to point to both the increasing level of transplant physician care as well as to the high degree of efficacy of our cord blood units.”
To find out more visit StemCyte online at www.stemcyte.com.
About StemCyte, Inc.
StemCyte, Inc., headquartered in Arcadia, California, intends to create the largest donor umbilical cord blood stem cell bank in the world. StemCyte and its subsidiaries are dedicated to providing high quality, cost-effective, stem cell transplantation and therapy to all patients in need. StemCyte is accredited by American Association of Blood Banks (AABB), the College of American Pathologists (CAP), and the National Marrow Donor Program (NMDP). Additionally, the StemCyte International Cord Blood Center is accredited by the Foundation for Accreditation of Cellular Therapies (FACT) for cord blood collection, processing, testing, banking, selection and release, and is the first and the only cord blood bank in the world accredited by FACT for autologous donations.
CONTACT: David Carmel
StemCyte, Inc. 917-414-4121
StemCyte, Inc.
CONTACT: David Carmel of StemCyte, Inc., +1-917-414-4121
Web site: http://www.stemcyte.com/
